Disclaimer

This documentation is a presentation (the "Presentation") of general background information about Cryomass Technologies Inc. ("CryoMass" or "the Company"). It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities of CryoMass are reminded that any such purchase or subscription must not be made on the basis of the information contained in this Presentation but are referred to the entire body of publicly disclosed information regarding CryoMass. The information contained in this Presentation is derived solely from management of CryoMass and otherwise publicly available information concerning CryoMass and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in CryoMass.

The information has not been independently verified and is subject to material updating, revision and further amendment, and is qualified entirely by reference to CryoMass' publicly disclosed information. No representation or warranty, express or implied, is made or given by or on behalf of CryoMass or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. CryoMass does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.

Certain information set forth in this Presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contains

herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, any investment solicited; (iii) the expected development of the Company's business, projects, and agreements; (iv) execution of the Company's vision and growth strategy, including with respect to future contractual activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company's material agreements; (vii) future liquidity, working capital, and capital requirements; and (viii) financial results, future financial position, expected growth of cash flows, business strategy, budgets, projected costs, projected capital expenditures, taxes, plans, objectives, potential synergies, industry trends and growth opportunities. Often but not always, forward-looking information can be identified by the use of words such as "anticipate", "believe", "expect", "project", "estimate", "likely", "intend", "should", "could", "may", "might", "target", "plan" and other similar expressions or variations (including negative variations) of such words and phrases. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance, achievements and financial results of CryoMass in future periods to differ materially from any projections of future performance, achievements or financial results expressed or implied by such forward-looking statements.

These risks, uncertainties and other factors include, but are not limited to, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of CryoMass to implement its business strategies; competition; crop failure; currency and interest rate fluctuations, and the other risks. The foregoing factors are not intended to be exhaustive. Although CryoMass has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

outlook", under applicable securities laws (collectively referred to herein as forward-looking statements contained in this presentation are based upon looking statements). Except for statements of historical fact, the information contained what management of the Company believes are reasonable assumptions, there can be

no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements contained herein are made as of the date hereof and the Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. All forward-looking statements is expressly qualified in its entirety by this cautionary statement. Forward-looking statements and other information contained herein concerning management's general expectations concerning the cannabis industry are based on estimates prepared by management using data from publicly available industry sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which management believes to be reasonable. However, this data is inherently imprecise, although generally indicative of relative market positions, market shares and performance characteristics. While management is not aware of any misstatements regarding any industry data presented herein, industry data is subject to change based on various factors. This Presentation may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed in any other jurisdiction which prohibits the same except in compliance with applicable laws. Any failure to comply with this restriction may constitute a violation of applicable securities law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and CryoMass does not accept liability to any person in relation thereto.

Refinement Done More Efficiently

- CryoMass Technologies Inc. develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops.
- The company's patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes.



Two-Skids CryoSift Separator™ Production Model

Maximizing Returns for Cultivators and Processors of Premium Botanicals

- Building on this technology, CryoMass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™).
- Much like sugar and flour refinements, the resulting CryoSift™ concentrate is a superior product compared to unprocessed biomass.
- For cultivators, reducing biomass into CryoSift™ slashes volume up to 80%, dramatically lowering storage, handling, and transportation costs. Properly stored, CryoSift™ prevents potency and terpene degradation, preserving value.
- For processors, the minimized input volume also enables considerable cost savings and logistics advantages. Extracting from CryoSift™ using solvents and manufacturing solventless products unlocks industrial scale yields unattainable otherwise.
- CryoMass anticipates its efficiencies will catalyze industry-wide shifts in cannabis and hemp post-harvest methods. Additionally, the technology shows promise for diverse trichome-rich plants.




Hemp & Marijuana Are The Same Plant: Cannabis sativa

All forms of cannabis, including marijuana and hemp, belong to a single species - cannabis sativa.

HEMP

A term often used in policy to describe any cannabis variety with less than 0.3% THC.

Traditionally bred for CBD, fiber and seed



MARIJUANA

A vernacular term typically used to describe cannabis with higher levels of THC (over 10%).

Traditionally bred for cannabinoids – most notably THC

1. FLOWER

Often called buds, cannabis flowers vary in appearance depending on their sex and genetic traits. The colours range widely with the most common being green, orange, red and purple. The female flower, having the highest concentration of trichomes, is the part of the plant that is consumed to experience the effects attributed to cannabis.

2. TRICHOMES

Cannabis trichomes contain, in varying quantities, several cannabinoid compounds, predominantly tetrahydrocannabinol (THC) and cannabidiol (CBD). Trichomes appear as tiny crystals all over the plant. They are bigger and denser on the flowers than on the leaves.

3. LEAF

The symbol of the cannabis and something of an icon, the leaf is easily recognizable by its fan shape, pronounced venation and serrated leaflets. Leaf colour can range from pale green to dark olive green.

TERPENES


Different strains of cannabis have different sets of terpenes, which are comparable to essential oils. It is mainly the terpenes that give cannabis plants their particular aromas and flavours.



Importance Of Trichomes

Glandular trichomes are small resin glands found mostly on the surface of female flowers. These chemical factories produce hundreds of compounds including cannabinoids and terpenes. Cannabinoids, including THC and CBD, are responsible for the medicinal and sometimes psychoactive effects of cannabis.

Terpenes (and terpenoids) are largely responsible for the characteristic smell of cannabis as well as contributing to the medicinal effects. Cannabinoids and terpenes are found almost exclusively within the glandular trichomes and nowhere else on the plant. Not only are these compounds very sensitive to environmental factors such as oxygen, heat and light, the trichomes housing these compounds are very delicate and will readily fracture or detach when subjected to physical agitation.



Traditional Harvesting & Processing Methods Incur Enormous Loss Of Trichomes

Conventional processing methods haven't changed much since the 1960s, when the industry operated illegally out of someone's backyard. The methods waste a third or more of the plant's most desired elements – the trichomes.

The trouble starts with the **fragility of trichomes**. They break off easily and are lost forever in the same way a Christmas tree loses its needles when handled and then are gone forever. With conventional handling and drying, every step shakes off more of them. **All in all, roughly one-third of the trichomes are lost.**

When the plant is handled and trucked to a drying facility, the loss of trichomes accelerates. Then – midway through drying – the flower becomes extremely brittle and trichome loss becomes exponential, like the needles of a Christmas tree being forced through the front door at the end of the holiday season.

By that point, the plant still needs to be handled and transported to the extraction facility. The biggest challenge in any plant processing is to capture all the valuable elements that are wrapped up inside the plant at the moment of harvest.

There really was no way to accomplish this...until now.



What Have Trichomes Been Traditionally Used For?

Hashish, also known as hash, is a cannabis concentrate product composed of compressed or purified preparations of stalked resin glands, called trichomes.

Hash has a long history of usage in countries such as Morocco, Afghanistan, India, Iran, Israel, and Lebanon. The sticky resins glands of the fresh flowering female cannabis plant are collected. Traditionally this was, and still is, done in remote locations by pressing or rubbing the flowering plant between two hands and then forming the sticky resins into a small ball of hashish called charas. This method produces the highest amount of cannabinoids (THC content up to 60%) without chemical solvents or distillation.









Mechanical separation methods use physical action to remove the trichomes from the dried plant material, such as sieving through a screen by hand or in motorized tumblers. This technique is known as "drysifting". The resulting powder, referred to as "kief" or "drysift", is compressed with the aid of heat into blocks of hashish.

Ice-water separation is another mechanical method of isolating trichomes.

How Were Trichomes Collected Before CryoMass?

Traditional trichome separation methods are rudimentary at best.

The cannabis flower is typically placed in a mesh bag, soaked in ice water and then agitated to separate the trichomes.

The careful agitation is done by machine or by hand, using paddles. Trichomes may break away from supporting flower and leaves when plant material becomes brittle at low temperatures. After plant material has been agitated in an icy slush, separated trichomes are often dense enough to sink to the bottom of the ice-water mixture following agitation, while lighter pieces of leaves, stems and other plant particles tend to float. The water is then left to settle and the trichomes at bottom of the tank are isolated using filtration bags with various-sized screens.




Current Industry Challenges

- Harvesting, drying and freezing biomass is labor intensive and costly.
- Biomass handling causes significant trichome loss (30%+).
- Biomass high storage and transport costs due to large volumes and space needs.
- Biomass degradation occurs during storage and handling resulting from exposure to oxygen, moisture, light or heat
- Extraction from full biomass is a **lengthy and expensive** process.

CryoMass delivers a state-of-the-art technology solution that addresses all these challenges to increase profitability for our customers.



Delivering High-Value Process Improvements to Biomass Operators



ELIMINATE DRYING

Process fresh plants straight from the field and reduce days of work & trichome loss.

SCALABLE INDUSTRIAL CAPACITY

Process up to 700 lbs/317,500 grams of fresh biomass per hour per system.

MOBILE OR FIXED UNITS

Our system can be operated at the cultivation site or be permanently installed in a processing facility.

GREEN PROCESS

Minimal energy usage and no organic solvents. Minimal ecological footprint.

HIGHER OUTPUT

Increase cannabinoid and terpene concentration up to 10x.

BIOMASS VERSATILITY

Process wet or dry, fresh frozen, cured flower, trim and everything in between.

REDUCED VOLUME

Reduce volume of product up to 80% relative to starting material, making storage and transportation less burdensome.

SEPARATION EFFICIENCY

The process efficiently recovers up to 97% of available trichomes from biomass.

CryoMass vs. Traditional Trichome Separation Systems

CRYOMASS


TRADITIONAL

When comparing the results of the patented CryoMass system to traditional ice water trichome separation systems, there is no comparison.

Based on the processing of **25,000 lbs** of biomass, here is a comparison of our trichome separation system versus nine leading traditional systems that do not and cannot utilize our patented cryogenic, solventless separation process. **They use ice water instead.**

It is important to note that one of the key reasons the CryoMass system is so much more efficient from a process and cost-saving perspective is that it is, to the best of our knowledge, the only continuous-feed separation system while all others are batch-feed systems.

Although the Company's initial focus is on the cannabis and hemp sector, there is tremendous potential to generate important revenue streams from processing other high-value, trichome-rich plants where similar cost savings and end-product improvements can be realized.



^{*} Traditional systems data was gathered from company websites and from conversations with company representatives. This is an average of the 9 leading traditional systems.

Advantage #1 - Case Study Enhanced Hydrocarbon Extraction Yields from CryoSift vs. Full Biomass

Strain: Grapes & Cream

Biomass: Fresh Frozen

Solvent: Butane

Extract: Live Resin

Biomass processed (lb): 2,000

Biomass processed (kg): 907.18

Extraction results without CryoMass separation

Yield (%)	3.8%
Yield (kg)	34.47
Sale price per kg	\$ 2,500
Total revenue	\$ 86,175

Better Yields = More Revenue

Extraction results when using the CryoMass separation

Yield (%)	7.7%
Yield (kg)	69.85
Sale price per kg	\$ 2,500
Total revenue	\$ 174,625
Additional revenue	\$ 88,450
Additional revenue per lb processed	\$ 44.22

Advantage #2 - Case Study Cold Storage Cost of a Typical Cannabis Farm in California

Amount of biomass to store: 300,000 lbs

Storage container: 40-foot refrigerated container with diesel generator

Amount of biomass per container: 10,000 lbs

Number of containers required: 30

Monthly cost per container: \$4,500

CryoMass reduces the volume of biomass by up to 80 % Weight ≠ Volume

Storage costs without CryoMass separation

Number of containers	30
Total monthy storage cost	\$ 135,000

Storage costs when <u>using</u> the CryoMass separation

Number of containers required	6		
Total monthly storage cost	\$ 27,000		
Monthly cost savings	\$ 108,000		
Annual cost savings	\$ 1,296,000		
Annual cost saving per lb on 300k lbs	\$ 4.32		

We Call The Result Of Our Cryogenic Trichome Separation - CryoSiftTM

CRYOSIFT™ IS TRICHOMES IN THEIR PUREST FORM

- CryoSift™ can be used for making THC and CBD products for medicinal, wellness and recreational purposes. It can also be used for making CBD products for animals.
- The quality of CryoSift™ is superior to sift obtained with traditional dry and water-based trichome separation methods. Cryogenic separation results in increased cannabinoid yields, higher terpene count for a greater retention of the most desirable compounds.
- Though CryoSift[™] can be consumed as is, it is the ideal input for manufacturing superior premium concentrates at scale, without the use of solvents (solventless).
- CryoSift™ can also be used as a high-quality feedstock for traditional solvent-based extraction methods (such ethanol, CO2 or hydrocarbon) to create extracts with different flavor, color and aroma profiles like live resin concentrates.



CRYOSIFTTM




SOLVENTLESS PRODUCTS




SOLVENT BASED PRODUCTS

Attractive Opportunities in Botanical Extracts Markets

Cannabis and Hemp - Our First Major Markets



Global Botanical Extracts - The Future



^{*} Management estimates based on data compiled from a variety of sources, including, but not limited to: industry research reports, publicly-traded company filings, industry trade associations, trade publications and market research databases. Additional data regarding data sources available upon request.

Building A Sustainable Competitive Advantage

Strong IP portfolio

- US Patents: expiring in 2037 & 2038
- Canadian Patent: expiring 2038
- Chinese Patent: expiring 2038
- Patents pending in 5 other countries.
- Trademarks: CryoMass®, CryoSift™ and CryoSift Separator™

- Experienced in-house team of industry-leading experts.
- Established industry relationships.
- Extensive R&D and long learning curve.
- Significant capital invested to develop the technology and supporting processes.
- First mover advantage.

Strategic Partners and Customers

- Strategic Operational Partners are established, licensed biomass processors.
- Customers are existing, established cultivators and processors of biomass.



June 14th 2023, CryoMass first showcasing event for cultivators and processors from California and other states.

Recurring Revenue Model

- CryoMass licenses its patented technology by renting CryoSift Separators™ to partners who provide biomass refinement services to cultivators and processors of premium crops.
- Our licensing model generates recurring revenue by charging partners a royalty per pound of biomass processed through the CryoSift Separators™.

Example of Recurring Royalties per Unit

Year	2024		2025	2026	2027	2028
Pounds of biomass per day processed by the CryoSift Separator™	1,0	00	1,200	1,400	1,600	1,800
Number of days of processing per week		4	4	4	4	4
Amount of biomass processed per week (lb)	4,0	00	4,800	5,600	6,400	7,200
Amount of biomass processed per month (lb)	16,0	00	19,200	22,400	25,600	28,800
Amount of biomass processed per year (lb)	192,0	00	230,400	268,800	307,200	345,600
Royalty per pound paid to CryoMass	\$ 5	00	\$ 5.00	\$ 5.00	\$ 5.00	\$ 5.00
Annual royalty paid to CryoMass by the licensee per unit	\$ 960,0	00	\$ 1,152,000	\$ 1,344,000	\$ 1,536,000	\$ 1,728,000

CryoSift Separator™ Unit Deployment Targets

Year	2024	2025	2026	2027	2028
CryoSift Separators™ deployed during the year	3	4	4	6	8
Total CryoSift Separators™ deployed at year end *	4	8	12	18	26

^{* 2024} Includes 1 CryoSift Separator™ deployed during 2023

CryoSift Separators™ Cannabis & Hemp Markets

- Leads: 200+ inquiries received from 10+ countries and 20+ US States.
- Prospects: 70+ conversations.
- Opportunities: 25+ active conversations.
- Targets: 2 short term deployments.
- Operational: 1 CryoSift Separator™ in California, USA.

Initial Market Focus Is
North America

CALIFORNIA

1st CryoSift Separator™ at operating partner facility can cover 60% of California cultivation licenses.

Legal Cannabis product sales in California totalled US\$431.3 million in June 2022.

Suggesting an annual run-rate of US\$5.175 billion⁽⁶⁾

Global cannabis product sales are projected to reach US\$61 billion by 2026 (1)

CANADA CANNABIS

Product sales of US\$4 billion in 2021 projected to be US\$7.6 billion in 2026 (2)

2,196 acres of licensed cultivation in 2021 (3)

CANADA HEMP

1,269 industrial hemp licenses in 2020 with 54,963 acres of cultivation (5)

USA CANNABIS

Product sales projected to grow from US\$18.5 billion in 2022 to US\$58.8 billion in 2026 (2)

USA HEMP

In 2021, 30,000 acres of hemp were harvested for a total of ~30 million pounds of biomass (4)

- https://bdsa.com/wp-content/uploads/2022/03/Cannabis-Market-Forecast-Spring-2022-Update.pdf
- 2. https://prohibitionpartners.com/2022/08/04/the-north-american-cannabis-report-3rd-edition-key-insights/
- 3. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/market/licensed-area.html
- 4. https://www.hempbenchmarks.com/interactive/total-us-hemp-acres-permitted-planted-harvested/
- 5. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/producing-selling-hemp/about-hemp-canada-hemp-industry/statistics-reports-fact-sheets-hemp.html
- 6. https://www.newcannabisventures.com/june-cannabis-sales-decrease-slightly-from-may-to-1-65-billion/



Christian Noël CEO

Seasoned wealth advisor, investor and cannabis industry expert leveraging over 20 years of capital markets expertise to drive growth opportunities.



Aaron GodinDirector of Applied Science

A Master agrologist with a passion for everything driven by science and data.



Blair Mullin CFO

Decades of CFO leadership spanning high-growth startups to public companies across technology, manufacturing, and emerging industries.



Mike Stringile
Director of Int'l Sales

Extraction technology expert leveraging 7+ years of oil, gas and cannabis industry experience to drive innovative solutions and sales growth.



Patricia Kovacevic General Counsel & Head of External Affairs

Accomplished legal expert and strategist with decades of experience navigating complex regulations for global corporations across multiple industries.



Steve Cimini
Director of US Sales

Cannabis industry pioneer and sales leader instrumental in developing revolutionary extraction technologies and achieving tremendous market growth.



Matt Armstrong
Sr. Director of Innovation

Decorated Marine veteran and technical visionary leading cutting-edge cryogenic innovation in agricultural extraction technology.



Priyesh SharmaSr. Director of Engineering and R&D

Engineering leader with 20+ years' experience driving innovation from concept to commercialization across agriculture, energy, aerospace, and other industries.

Board Of Directors



Dr. Delon HumanChairman of the Board

Accomplished physician, author and global health strategist advising international organizations, governments and corporations on healthcare access, harm reduction, and product transformation.



Mario Gobbo Director

Seasoned investment banker and biotech advisor with 35+ years spanning healthcare, life sciences, and energy sectors across emerging and developed markets.




Mark Radke Director

Preeminent securities lawyer and former SEC Chief of Staff advising financial services institutions on regulatory compliance, governance, and strategic initiatives.



Simon Langelier Director

Global tobacco executive with 30+ years of leadership spanning new product innovation, international markets, and strategic board governance.



A Game-Changing Opportunity

MARKET

Large & rapidly growing market opportunity for premium botanical extracts of \$25B today to more than \$95B in 2030.

TECHNOLOGYSuperior patented technology for premium botanical refinement delivers efficient, high value solution to customers.

ECONOMICS Attractive, high margin recurring revenue model.

P Solid IP portfolio - patented core technology.

UNPARALLELEDLimited competition from inferior refinement methodologies.

TEAMExperienced senior management and Board with deep industry expertise and network.

To Learn More

The common stock of CryoMass Technologies Inc. trades on the OTCQB market under the symbol **CRYM**.

For further information, please contact us using a method below:

investors@cryomass.com

+1 (833) 256-2382

or +1 (303) 222-8092

WE WELCOME YOUR INQUIRIES